Literature DB >> 26787496

[New drugs for treatment of tuberculosis].

T Schaberg1.   

Abstract

New effective drugs for the treatment of tuberculosis (TB) are necessary for two main reasons: firstly, it would be desirable to reduce the duration of TB treatment from 6 to 4 months and secondly, new drugs are urgently needed for the treatment of multidrug-resistant strains of Mycobacterium tuberculosis. For the first time since 1960 the two new drugs bedaquiline and delamanid were approved and licensed in 2014 for the treatment of multidrug-resistant M. tuberculosis; however, efforts to reduce the duration of treatment to 4 months using fluoroquinolones have not been successful. Further new drugs are currently in phase 2 and phase 3 studies; therefore, new treatment options can be expected within the next few years.

Entities:  

Keywords:  Bedaquiline; Delamanid; Fluoroquinolones; PA-824; Tuberculosis, multidrug resistant

Mesh：

Substances：

Year:  2016        PMID： 26787496     DOI： 10.1007/s00108-015-0011-9

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN： 0020-9554            Impact factor:   0.743


  19 in total

1.  Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis.

Authors:  Armand Van Deun; Aung Kya Jai Maug; Md Abdul Hamid Salim; Pankaj Kumar Das; Mihir Ranjan Sarker; Paul Daru; Hans L Rieder
Journal:  Am J Respir Crit Care Med       Date:  2010-05-04       Impact factor: 21.405

2.  Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles.

Authors:  Hirofumi Sasaki; Yoshikazu Haraguchi; Motohiro Itotani; Hideaki Kuroda; Hiroyuki Hashizume; Tatsuo Tomishige; Masanori Kawasaki; Makoto Matsumoto; Makoto Komatsu; Hidetsugu Tsubouchi
Journal:  J Med Chem       Date:  2006-12-28       Impact factor: 7.446

3.  The diarylquinoline TMC207 for multidrug-resistant tuberculosis.

Authors:  Andreas H Diacon; Alexander Pym; Martin Grobusch; Ramonde Patientia; Roxana Rustomjee; Liesl Page-Shipp; Christoffel Pistorius; Rene Krause; Mampedi Bogoshi; Gavin Churchyard; Amour Venter; Jenny Allen; Juan Carlos Palomino; Tine De Marez; Rolf P G van Heeswijk; Nacer Lounis; Paul Meyvisch; Johan Verbeeck; Wim Parys; Karel de Beule; Koen Andries; David F Mc Neeley
Journal:  N Engl J Med       Date:  2009-06-04       Impact factor: 91.245

4.  Phase II dose-ranging trial of the early bactericidal activity of PA-824.

Authors:  Andreas H Diacon; Rodney Dawson; Jeannine du Bois; Kim Narunsky; Amour Venter; Peter R Donald; Christo van Niekerk; Ngozi Erondu; Ann M Ginsberg; Piet Becker; Melvin K Spigelman
Journal:  Antimicrob Agents Chemother       Date:  2012-03-19       Impact factor: 5.191

5.  Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China.

Authors:  Shenjie Tang; Lan Yao; Xiaohui Hao; Xia Zhang; Gang Liu; Xin Liu; Meiying Wu; Linhai Zen; Hua Sun; Yidian Liu; Jin Gu; Feishen Lin; Xiafang Wang; Zhanjun Zhang
Journal:  Eur Respir J       Date:  2014-09-18       Impact factor: 16.671

Review 6.  Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications.

Authors:  W Fox; G A Ellard; D A Mitchison
Journal:  Int J Tuberc Lung Dis       Date:  1999-10       Impact factor: 2.373

7.  The emergence of drug-resistant tuberculosis in New York City.

Authors:  T R Frieden; T Sterling; A Pablos-Mendez; J O Kilburn; G M Cauthen; S W Dooley
Journal:  N Engl J Med       Date:  1993-02-25       Impact factor: 91.245

8.  Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.

Authors:  Won-Jung Koh; O Jung Kwon; Hyesun Gwak; Joo Won Chung; Sang-Nae Cho; Woo Sung Kim; Tae Sun Shim
Journal:  J Antimicrob Chemother       Date:  2009-05-25       Impact factor: 5.790

9.  Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis.

Authors:  Vija Skripconoka; Manfred Danilovits; Lea Pehme; Tarmo Tomson; Girts Skenders; Tiina Kummik; Andra Cirule; Vaira Leimane; Anu Kurve; Klavdia Levina; Lawrence J Geiter; Davide Manissero; Charles D Wells
Journal:  Eur Respir J       Date:  2012-09-27       Impact factor: 16.671

10.  OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.

Authors:  Makoto Matsumoto; Hiroyuki Hashizume; Tatsuo Tomishige; Masanori Kawasaki; Hidetsugu Tsubouchi; Hirofumi Sasaki; Yoshihiko Shimokawa; Makoto Komatsu
Journal:  PLoS Med       Date:  2006-11       Impact factor: 11.069
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.